

Cover Story
News Analysis
For over a month since President Trump announced his intent to impose aggressive new tariffs on America’s friends and foes alike, lobbyists for hospitals, medical societies, and makers of branded and generic drugs have been trying to convince him to rethink.
In Brief


Clinical Roundup


Drugs & Targets
Trending Stories
- Lou Weiner: Poetry and art help us imagine my mother’s world as a hidden child of the Holocaust
- ACOG says it will no longer accept federal funding
- GOP-led Congress rejects Trump’s plans to gut medical research
Senate bill gives NIH a $400 million raise - Vinay Prasad falls from grace at FDA upon flunking Trump political purity test
MAHA leaders agree on one point: COVID was mishandled. Is that enough to run science-based agencies? - Andrea Werblin Reid’s unflinching poetry documents the realities of cancer care, clinical trials, and loss
Her collection, “To See Yourself As You Vanish,” will be published three years after her death - Brown University reaches agreement with Trump administration to restore funding